Table 2 Summarization of HIV-infected individuals’ demographic data, clinical presentation and treatment outcome of COVID-19
From: COVID-19 and HIV infection co-pandemics and their impact: a review of the literature
| Â | Hsi-en Ho, et al. [43] | Sigel et al. [49] | Vizcarra et al. [41] | Gervasoni et al. [54] | Meyerowitz et al. [55] | Shalev et al. [45] | Byrd et al. [52] | Okoh et al. [44] | Childs et al. [53] | Suwanwongse et al. [46] | Guo et al. [42] |
|---|---|---|---|---|---|---|---|---|---|---|---|
No. of patients | 93 | 88 | 51 | 47 | 36 | 31 | 27 | 27 | 18 | 9 | 8 |
Country | USA, New york | USA, New york | Spain | Italy | USA, Boston | USA, New york | USA, Rhode Island | USA, New Jersey | United Kingdom | USA, New york | China, Wuhan |
Median age, Years (median, IQR) | 58 (52–65) | 61 (54–67) | 53 (Mean; range 31–75) | 51 ± 12 (Mean ± SD) | 53 (Mean; range 24–81) | 60.7 (Mean; range 23–89) | 51 (40.5–57) | 58 (50–67) | 52 (49–58) | 58 (52–70) | 57 (48–62) |
Male, n (%) | 67 (72%) | 66 (75%) | 43 (84%) | 36 (76%) | 21 (58%) | 24 (77%) | 21 (78%) | 15 (55%) | 12 (67%) | 7 (78%) | 7 (88%) |
Comorbidities, n (%) | |||||||||||
 Hypertension | 49(53%) | 33 (38%) | 18 (35%) | 14 (30%) | 11 (31%) | 21 (68%) | 6 (22%) | 16 (59%) | 6 (33%) | 5 (56%) | NA |
 Diabetes mellitus | 32(34%) | 24 (27%) | 7 (14%) | 3 (6%) | 8 (22%) | 13 (42%) | 4 (15%) | 9 (33%) | 4 (22%) | 3 (33%) | NA |
 Chronic kidney disease | 16(17%) | 19 (22%) | 6 (12%) | 4 (9%) | 8 (22%) | 7 (23%) | 1 (4%) | 10 (27%) | 5 (28%) | NA | NA |
HIV clinical characteristics | |||||||||||
 Time since HIV diagnosis, years, (median, IQR) | 20 (15–26)d | NA | 19.5 (9.3–28.6) | NA | NA | NA | 10 (5.5–16.5) | NA | 14.6 (9.7–23.4) | NA | NA |
 Preadmission CD4 count, cells/μLc (median, IQR) | 554 (339–752)e | NA | 565 (296–782) | 636 ± 290 (Mean ± SD) | 660 (382–949) | 396 (Mean; range 89–924)k | 644 (359–775) | 551 (286–710) | 395 (238–680) | 465 (376–652)o | 546 (295–709) |
 Preadmission HIV RNA < 200 copies/mL, n (%) | 57 (84%)f | 66 (81%)l | 50 (98%) | 44 (94%) | NA | 30 (96.8%)k | 27 (100%) | 26 (96%)i | 17 (94%) | 8 (100%)o | 8 (100%) |
COVID-19 clinical presentations | |||||||||||
 Time since onset of COVID-19 symptoms to admission or diagnosis, Days, median (IQR) | NA | NA | NA | NA | 5.7 (Mean) | NA | 5(2.5-8)a | NA | 8 (7–10) | NA | NA |
Presenting symptoms, n (%) | |||||||||||
 Fever | 61 (66%) | NA | 36 (71%) | 41 | 21 (58%) | 23 (74%) | 9 (33%) | 17 (63%) | 11 (61%) | 5 (56%) | NA |
 Cough | 71 (76% | NA | 37 (73%) | 23 | 20 (56%) | NA | 6 (22%) | 18 (67%) | 13 (72%) | 6 (67%) | NA |
 Shortness of breath or dyspnea | 57 (61%) | NA | 28 (55%) | 10 | 14 (39%) | NA | 9 (33%) | 17 (63%) | 12 (67%) | 6 (67%) | NA |
Infiltrates on radiograph, n (%) | 71 (79%)g | NA | NA | 12 (25%)c | NA | 20 (65%) | 13(48%)b | NA | 13 (72%) | 8 (89%) | NA |
Needed Mechanical ventilation, n (%) | 15(21%) | 21%m | 5 (10%) | 2(4%) | 7(19%) | 8 (26%) | NA | NA | 5 (28%) | 5 (56%) | NA |
COVID severity, n (%) | Most mild to moderate | Most mild to moderate | Mild or moderate: 38 (75%), Severe: 13 (25%) | Most mild to moderate | Most mild to moderate | Most severe (68%) | Most mild to moderate | Most mild to moderate | Most mild to moderate | Most severe | Most mild to moderate |
Outcome of COVID-19, n (%) | |||||||||||
 Cure or discharge | 53 (74%)h | 70(79%)n | 44 (86%) | 45(96%) | 30(83%) | 21 (68%) | 26(96%) | 25(85%) | 12(67%) | 2(22%) | NA |
 Hospitalized | 0 (%) | NA | 5 (10%) | NA | 4 (11%) | 2 (7%) | 0 (0%) | NA | 1 (5%) | 0 (%) | NA |
 Died | 19 (26%)h | 18(21%) | 2 (4%) | 2 (4%) | 2 (6%) | 8 (26%) | 1 (4%) | 2 (15%) | 5 (28%) | 7 (78%) | 1 (12.5%) |